DE69738640T2 - Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze - Google Patents

Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze Download PDF

Info

Publication number
DE69738640T2
DE69738640T2 DE69738640T DE69738640T DE69738640T2 DE 69738640 T2 DE69738640 T2 DE 69738640T2 DE 69738640 T DE69738640 T DE 69738640T DE 69738640 T DE69738640 T DE 69738640T DE 69738640 T2 DE69738640 T2 DE 69738640T2
Authority
DE
Germany
Prior art keywords
gene
cells
use according
expression
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69738640T
Other languages
German (de)
English (en)
Other versions
DE69738640D1 (de
Inventor
Chrit Bethesda MOONEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of DE69738640D1 publication Critical patent/DE69738640D1/de
Application granted granted Critical
Publication of DE69738640T2 publication Critical patent/DE69738640T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69738640T 1996-08-15 1997-08-14 Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze Expired - Fee Related DE69738640T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2421396P 1996-08-15 1996-08-15
US24213P 1996-08-15
PCT/US1997/015270 WO1998006864A2 (en) 1996-08-15 1997-08-14 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat

Publications (2)

Publication Number Publication Date
DE69738640D1 DE69738640D1 (de) 2008-05-29
DE69738640T2 true DE69738640T2 (de) 2009-07-16

Family

ID=21819426

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738640T Expired - Fee Related DE69738640T2 (de) 1996-08-15 1997-08-14 Räumliche und temporäre kontrolle der genexpression mittels eines hitzeschockproteinpromotors in kombination mit lokaler hitze

Country Status (8)

Country Link
US (2) US7186698B2 (enExample)
EP (1) EP0922110B1 (enExample)
JP (2) JP2001501458A (enExample)
AT (1) ATE392481T1 (enExample)
AU (1) AU732872C (enExample)
CA (1) CA2263706A1 (enExample)
DE (1) DE69738640T2 (enExample)
WO (1) WO1998006864A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342596B1 (en) 1998-05-05 2002-01-29 Hsf Pharmaceuticals S.A. Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
EP1109582A4 (en) * 1998-08-18 2004-11-03 Res Dev Foundation METHOD FOR STRENGTHENING AND RESTRICTING GENE EXPRESSION
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6684097B1 (en) 1999-04-22 2004-01-27 University Of Miami Intraoperative monitoring of temperature-induced tissue changes with a high-resolution digital x-ray system during thermotherapy
AU7841400A (en) * 1999-10-01 2001-05-10 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
US6953659B2 (en) * 2000-07-14 2005-10-11 Massachusetts Institute Of Technology Direct, externally imposed control of nucleic acids
CA2349506C (en) 2001-06-14 2009-12-08 Duke University A method for selective expression of therapeutic genes by hyperthermia
WO2003006608A2 (en) 2001-07-10 2003-01-23 Davidson Michael N Enhancement of transfection of dna into the liver
CA2369985A1 (en) * 2002-01-18 2003-07-18 Duke University Generation of recombinant adeno-associated viral vectors by a complete adenovirus-mediated approach
EP1639115A1 (en) * 2003-06-19 2006-03-29 Peter Bromley Protein production system
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
AT500838B1 (de) * 2004-04-20 2007-11-15 Veterinaermedizinische Uni Wie Multiple hse
JP2008540347A (ja) * 2005-05-03 2008-11-20 フェテリネールメディツィニシュ ウニベルジテート ウィーン 浸透性カプセル
JP2009502180A (ja) 2005-08-03 2009-01-29 アデレイド リサーチ アンド イノベーション ピーティーワイ リミテッド 多糖シンターゼ
US7774057B2 (en) * 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
US20070190028A1 (en) * 2006-02-13 2007-08-16 Jihong Qu Method and apparatus for heat or electromagnetic control of gene expression
US7871406B2 (en) * 2006-08-04 2011-01-18 INTIO, Inc. Methods for planning and performing thermal ablation
EP2056711B1 (en) * 2006-08-22 2011-03-02 Koninklijke Philips Electronics N.V. Device for obtaining information about a mammalian body
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
CN102388142B (zh) 2008-11-28 2014-08-06 巴西农业研究公司-恩布拉帕 启动子元件中AT(n)插入在控制植物编码序列的表达水平中的用途
US20110127254A1 (en) * 2009-11-30 2011-06-02 Cypress Technology Llc Electric Heating Systems and Associated Methods
US9848950B2 (en) 2012-04-27 2017-12-26 Medtronic Ardian Luxembourg S.A.R.L. Methods and devices for localized disease treatment by ablation
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
KR20160107303A (ko) * 2014-01-17 2016-09-13 웨이크 포리스트 유니버시티 헬스 사이언시즈 활성 작용제 전달의 강화 방법
US11504427B2 (en) * 2016-11-22 2022-11-22 The Regents Of The University Of California Acoustic and ultrasound-based mechanogenetics and thermogenetics for immunotherapy
US11318330B2 (en) * 2018-09-26 2022-05-03 General Electric Company Neuromodulation techniques
US20220241337A1 (en) * 2019-02-22 2022-08-04 The Trustees Of Columbia University In The City Of Newyork Preparing tissues for delivery of therapeutic and diagnostic agents and delivering the agents
US20220298515A1 (en) * 2019-09-10 2022-09-22 The Regents Of The University Of California Ultrasound-based thermogenetics for immunotherapy
US11176717B2 (en) * 2019-09-26 2021-11-16 Siemens Healthcare Gmbh Guiding protocol development for magnetic resonance thermometry
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
EP4136228A4 (en) * 2020-04-15 2024-09-11 California Institute of Technology THERMAL REGULATION OF T-CELL IMMUNOTHERAPY BY MOLECULAR AND PHYSICAL ACTUATION

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO172595C (no) 1983-02-07 1993-08-11 Battelle Memorial Institute Fremgangsmaate og ekspresjonsplasmid for fremstilling av hemagglutinin under kontroll av drosophila hsp-promoter
AU604214B2 (en) 1985-07-31 1990-12-13 Battelle Memorial Institute An improved heat-shock control method and system for the production of competent eukaryotic gene products
AU606049B2 (en) * 1986-02-06 1991-01-31 General Hospital Corporation, The Inducible heat shock and amplification system
WO1987005935A1 (en) * 1986-04-04 1987-10-08 Battelle Memorial Institute At Columbus, Ohio Gene Methods and compositions for expression of competent eukaryotic gene products
EP0263908B1 (en) * 1986-10-15 1991-09-25 Battelle Memorial Institute Method for the production of proteins by means of inducible expression systems in genetically modified eukaryotic host-cells multiplicated in-vivo
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
EP0299127A1 (en) * 1987-07-16 1989-01-18 IntraCel Corporation A method for the expression of recombinant genes under stimulation from an inducively expressed activator protein
ZA892518B (en) 1988-04-08 1989-12-27 Intracel Corp Method for the in-vivo production and testing of proteins by recombinant gene expression in selected host-cells
WO1990001543A1 (fr) * 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
DK0737750T3 (da) * 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5521084A (en) 1992-11-10 1996-05-28 Biostar, Inc. Bovine heat shock promoter and uses thereof
WO1995000178A1 (en) * 1993-06-25 1995-01-05 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy
US5979454A (en) * 1995-05-15 1999-11-09 The Regents Of The University Of California Method and apparatus for causing rapid and deep spatially selective coagulation during thermally mediated therapeutic procedures
US5490840A (en) * 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates

Also Published As

Publication number Publication date
WO1998006864A3 (en) 1998-05-14
AU732872C (en) 2002-02-21
JP2001501458A (ja) 2001-02-06
DE69738640D1 (de) 2008-05-29
AU732872B2 (en) 2001-05-03
ATE392481T1 (de) 2008-05-15
US20050059623A1 (en) 2005-03-17
US7186698B2 (en) 2007-03-06
EP0922110A2 (en) 1999-06-16
WO1998006864A2 (en) 1998-02-19
EP0922110B1 (en) 2008-04-16
US20020165191A1 (en) 2002-11-07
AU4241697A (en) 1998-03-06
JP2008291043A (ja) 2008-12-04
CA2263706A1 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
EP0922110B1 (en) Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat
DE69827021T2 (de) An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
Simari et al. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries.
DE69232497T2 (de) Behandlung von krankheiten durch ortsspezifische instillation von zellen oder ortsspezifische transformation von zellen sowie ausrüstung dafür
US6057300A (en) Methods for treating cancers and restenosis with p21
EP1687032B1 (en) Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
DE69526853T2 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
DE69230506T2 (de) Lymphokine gentherapie bei krebs in kombination mit tumorantigenen
DE69836139T2 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
JP4213201B2 (ja) 固型腫瘍、乳頭腫および疣贅の遺伝子治療
DE69313443T2 (de) Warte-effekt bei tumorzerstörender therapie
US20030086903A1 (en) Therapeutic regimen for treating cancer
US6794376B2 (en) Methods and compositions for enhancing diffusion of therapeutic agents through tissue
EP1443970B1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
EP0879294B1 (en) Transduced human hematopoietic stem cells
US7087582B1 (en) Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
AU2002224002C1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
WO2000078939A2 (de) Vektoren zur gentherapeutischen tumorbehandlung
HK1068057B (en) Promoters exhibiting endothelial cell specificity and methods of using same
IL155940A (en) Promoters unique to endothelial cells and methods of using them
AU2002224002A1 (en) Promoters exhibiting endothelial cell specificity and methods of using same
HK1158529B (en) Promoters exhibiting endothelial cell specificity and methods of using same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee